These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36997081)

  • 1. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study.
    Lazorwitz A; Sheeder J; Teal S
    Contraception; 2023 Jul; 123():110035. PubMed ID: 36997081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users.
    Lazorwitz A; Davis A; Swartz M; Guiahi M
    Contraception; 2017 Jun; 95(6):571-577. PubMed ID: 28288788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of double vs single-dose etonogestrel implant to overcome the interaction with efavirenz-based antiretroviral therapy.
    Chappell CA; Lamorde M; Nakalema S; Kyohairwe I; Byakika-Kibwika P; Meyn LA; Pham MM; Scarsi KK
    Am J Obstet Gynecol; 2024 Aug; 231(2):242.e1-242.e9. PubMed ID: 38458408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users.
    Lazorwitz A; Pena M; Sheeder J; Teal S
    Obstet Gynecol; 2022 Apr; 139(4):579-587. PubMed ID: 35594123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users.
    Lazorwitz A; Aquilante CL; Sheeder J; Guiahi M; Teal S
    Contraception; 2019 Jul; 100(1):37-41. PubMed ID: 30980827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
    Clure C; Sheeder J; Lazorwitz A
    Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users.
    Lazorwitz A; Seale R; Davis A; Guiahi M
    Contraception; 2020 Jul; 102(1):58-60. PubMed ID: 32325076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users.
    Diamond B; Sheeder J; Lazorwitz A
    Contraception; 2024 Jan; 129():110298. PubMed ID: 37802462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: a randomized controlled trial.
    Simmons KB; Edelman AB; Fu R; Jensen JT
    Contraception; 2017 Feb; 95(2):198-204. PubMed ID: 27725164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
    Bahamondes L; Brache V; Ali M; Habib N;
    Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period.
    Lazorwitz A; Sheeder J; Teal S
    Contraception; 2022 Apr; 108():65-68. PubMed ID: 34973207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy.
    Bishop IJ; Gertz AM; Simon B; Tawe L; Lechiile K; Liu S; Teodoro N; Mussa A; Avalos A; Malima S; Maotwe T; Mokganya L; Westhoff CL; Morroni C
    Contraception; 2020 Sep; 102(3):174-179. PubMed ID: 32387328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in body composition in women using long-acting reversible contraception.
    Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
    Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration.
    McNicholas C; Maddipati R; Zhao Q; Swor E; Peipert JF
    Obstet Gynecol; 2015 Mar; 125(3):599-604. PubMed ID: 25730221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
    Lazorwitz A; Aquilante CL; Oreschak K; Sheeder J; Guiahi M; Teal S
    Obstet Gynecol; 2019 Apr; 133(4):783-794. PubMed ID: 30870275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic evaluation of the etonogestrel contraceptive implant initiated midcycle with and without ulipristal acetate: An exploratory study.
    Gawron LM; Kaiser JE; Gero A; Sanders JN; Johnstone EB; Turok DK
    Contraception; 2024 Apr; 132():110370. PubMed ID: 38232940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood.
    Haddad LB; Swaims-Kohlmeier A; Mehta CC; Haaland RE; Brown NL; Sheth AN; Chien H; Titanji K; Achilles SL; Lupo D; Hart CE; Ofotokun I
    PLoS One; 2020; 15(3):e0230473. PubMed ID: 32214321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.